Clot Management Devices Market By Product (Mechanical Thrombectomy Systems, Aspiration Thrombectomy Systems, Stent Retrievers, Pharmacomechanical Thrombectomy Systems, Rheolytic Thrombectomy Systems, Catheter-Directed Thrombolysis Devices, Inferior Vena Cava Filters, Aspiration Pumps and Control Consoles, Thrombectomy Catheters and Access Components); By Application (Acute Ischemic Stroke, Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Peripheral Arterial Thrombosis, Thrombosed Dialysis Access, Intracardiac and Other Large-Vessel Thrombus); By End User (Hospitals, Comprehensive Stroke Centers, Cardiac Catheterization Laboratories, Interventional Radiology Centers, Vascular Surgery Centers, Ambulatory Surgical Centers, Office-Based Laboratories, Dialysis Access Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Clot Management Devices Market: Emergency Vascular Care Becomes a Multi-Vessel Device Business

The Global Clot Management Devices Market is valued at USD 2.24 billion in 2025 and is projected to reach USD 3.58 billion by 2032, growing at a sustained CAGR of 6.9%, according to Strategic Market Research. The forecast represents an absolute revenue increase of USD 1.34 billion, with the market expanding by approximately 59.8% over the seven-year period.

 

Interventional thrombus-management products are used to extract, aspirate, fragment, dissolve, or intercept thrombus within the vascular system. Key products are aspiration thrombectomy catheters, stent retrievers, mechanical thrombectomy systems, pharmacomechanical systems, catheter-directed thrombolysis devices, aspiration pumps, clot-capture accessories, and inferior vena cava filters. Main applications are acute ischemic stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia, thrombosed dialysis access, and selected large-vessel or intracardiac thrombi.

 

Revenue is generated mainly through hospital procedures that use sterile single-use catheters and supporting components. A thrombectomy may require an access sheath, aspiration catheter, retrieval device, tubing, canister, guidewire, pump, and multiple passes. Procedure volume is therefore a better commercial indicator than device-unit sales. Overall disease prevalence also overstates the number of patients eligible for intervention.

 

Purchasing decisions are made across emergency stroke, neurointerventional, cardiovascular, vascular surgery, and interventional radiology pathways. In the United States, reimbursement is generally tied to the diagnosis and procedure rather than a specific device. Manufacturers must show that their systems can shorten procedure time, reduce intensive-care use, limit blood loss, improve thrombus removal, or lower downstream disability without increasing the overall cost of care. Penumbra reported that hospitals are its primary U.S. customers. It also stated that approximately 90% of 2025 revenue was generated through direct sales. This highlights the importance of physician training and account-level clinical support.

 

Disease Burden Creates a Large Pool, but Eligibility Determines Revenue

Stroke provides the largest documented clinical population associated with clot-removal devices. More than 795,000 people experience a stroke annually in the United States, and approximately 87% of these events are ischemic. This places the broad U.S. ischemic-stroke pool at nearly 692,000 annual events, although only a smaller share involves an accessible large-vessel occlusion suitable for mechanical thrombectomy. Globally, the World Health Organization recorded 93.8 million existing stroke cases and 11.9 million new cases in 2021.

Venous thromboembolism adds a second major patient pool. Up to 900,000 people are affected by VTE in the United States each year, with an estimated 60,000–100,000 associated deaths. A Lancet review estimated that VTE, comprising deep vein thrombosis and pulmonary embolism, affects nearly 10 million people worldwide annually. Anticoagulation remains appropriate for most patients, while devices are reserved mainly for patients with severe symptoms, cardiopulmonary compromise, extensive clot burden, limb threat, contraindications, or treatment failure.

Commercial demand depends less on total incidence than on the proportion of patients who undergo procedures. Imaging access, emergency transport, specialist availability, reimbursement, hospital protocols, and proximity to thrombectomy-capable centers influence whether an eligible patient receives device-based treatment. This conversion gap allows procedural revenue to grow faster than the disease population as hospitals expand treatment capacity or extend patient eligibility.

 

Stroke Thrombectomy Remains the Established Revenue Base

Mechanical thrombectomy is an established intervention for eligible acute ischemic strokes caused by major vessel occlusion. An analysis of U.S. procedure and hospitalization data estimated 39,164 mechanical thrombectomies in 2021. Compared with Penumbra’s estimate of approximately 200,000 potentially treatable U.S. ischemic-stroke patients, completed procedures represented less than one-fifth of the manufacturer-estimated addressable population. Penumbra also estimates that 1.9 million patients outside the United States may be treatable with mechanical thrombectomy.

The difference between potential eligibility and completed procedures represents a major commercial opportunity. Research covering 11 U.S. states found that fewer than half of ischemic-stroke patients initially received care at a facility capable of performing mechanical thrombectomy. International access remains even more uneven, with treatment-center density, operator availability, ambulance routing, insurance coverage, and national income strongly affecting utilization.

Manufacturers cannot close this gap through product launches alone. Stroke-center accreditation, advanced imaging, round-the-clock staffing, interhospital transfer networks and neurointerventional training must advance with device availability. Suppliers that help hospitals build complete stroke pathways can achieve stronger account retention and recurring disposable revenue than those competing mainly on catheter design.

Competition is also moving beyond conventional aspiration and stent retrieval. Penumbra received U.S. FDA clearance in June 2026 for THUNDERBOLT, a computer-assisted aspiration platform for acute ischemic stroke. The company also began the FORWARD real-world study in July 2026 to evaluate mechanical and computer-assisted thrombectomy in selected distal M2 occlusions, with planned enrollment of up to 250 participants across approximately 40 sites. Expansion into smaller and more distal vessels could increase procedure volumes, but adoption will depend on evidence that treatment benefit outweighs hemorrhage, vessel injury, and patient-selection risks.

 

Pulmonary Embolism and DVT Reshape the Competitive Map

Pulmonary embolism and deep vein thrombosis have become the main expansion field for large-bore aspiration, mechanical extraction, and catheter-directed thrombolysis systems. A U.S. administrative-data study identified 145,870 VTE patients or encounters receiving mechanical thrombectomy or catheter-directed thrombolysis between 2016 and 2020. The total included 88,725 PE cases and 57,145 isolated DVT cases. Pulmonary embolism therefore represented approximately 60.8% of the combined advanced-intervention volume, while isolated DVT accounted for 39.2%.

The five-year total equals an average of approximately 29,174 advanced VTE interventions per year, although annual activity increased over the study period and the category combined mechanical thrombectomy with catheter-directed thrombolysis. The figures nevertheless show that PE has become the larger commercial subsegment within advanced VTE intervention.

The 2026 multisociety U.S. pulmonary embolism guideline provides a clearer framework for adoption. Anticoagulation remains the principal treatment for most acute PE cases, while catheter-based thrombolysis, mechanical thrombectomy, and surgical embolectomy are used mainly in higher-risk patients with hypotension, malperfusion, clinical deterioration, or severe cardiopulmonary compromise. Market growth will depend on identifying patients who gain sufficient clinical and economic benefit from early intervention.

Clinical competition is increasingly tied to hospital resource use. The PEERLESS trial compared large-bore mechanical thrombectomy with catheter-directed thrombolysis in intermediate-risk PE and favored mechanical thrombectomy on a hierarchical composite endpoint. The trial did not show a mortality difference but reported lower intensive-care utilization and fewer readmissions with large-bore thrombectomy. For hospital buyers, reduced ICU dependence and shorter recovery can be commercially important even when mortality differences are difficult to demonstrate.

Recent FDA clearances show that PE thrombectomy is attracting competitors beyond the largest vascular-device companies. Endovascular Engineering’s Helo system, Imperative Care’s Symphony system, and Inquis Medical’s Aventus system expanded the field for pulmonary and peripheral thrombus removal. These entries increase pressure on established suppliers to differentiate through blood-loss management, catheter navigability, clot-ingestion consistency, clinical evidence, and total procedure economics.

 

Peripheral and Dialysis-Access Cases Extend Device Utilization

Acute limb ischemia, thrombosed grafts, peripheral arterial occlusions, and dialysis-access thrombosis create smaller but commercially valuable extensions of the thrombectomy portfolio. These cases are treated in vascular operating rooms, interventional-radiology suites, catheterization laboratories, and specialized access centers, allowing companies with established hospital accounts to sell additional catheter sizes and indication-specific systems.

Stryker broadened its peripheral offering after acquiring Inari Medical in February 2025. The combined business launched Artix for peripheral arterial thrombus in March 2025 and introduced the next-generation InThrill system for small vessels and thrombosed arteriovenous fistulas and grafts in July 2025. Dialysis-access thrombosis differs commercially from stroke or PE because recurrent access failure can generate repeat interventions in the same patient, while treatment often includes correction of an underlying stenosis.

Penumbra began the STRIDE II study in 2025 to evaluate computer-assisted thrombectomy in lower-extremity acute limb ischemia. The earlier STRIDE study reported a 98.2% limb-salvage rate and 3.4% mortality at 30 days. The 94.8-percentage-point difference between limb salvage and mortality illustrates the clinical value suppliers are attempting to establish for rapid endovascular clot removal. Further comparative evidence will determine whether mechanical thrombectomy replaces catheter-directed lysis or open surgery in a larger share of arterial cases.

 

IVC Filters Shift Toward Restricted and Retrievable Use

Inferior vena cava filters remain part of the market but follow a different demand pattern. They intercept emboli in selected patients who cannot receive anticoagulation or remain at narrowly defined recurrent risk.

Approximately 40,000 IVC filters are placed annually in the United States, while utilization has declined as professional guidance and FDA safety communications have encouraged more selective placement and timely retrieval. Among Medicare fee-for-service beneficiaries, annual insertions fell from 44,680 in 2013 to 19,501 in 2021, representing a decline of approximately 56.4%.

Cumulative retrieval reached only 16.8% over the maximum nine-year follow-up, leaving more than four-fifths of filters unretrieved within the observed period. Nonretrieved filters remained associated with continuing risks of caval thrombosis and additional DVT events. This trend makes IVC filters a selective, compliance-sensitive subsegment rather than a leading contributor to the market’s 6.9% CAGR. Suppliers compete through retrievability, implantation control, patient tracking, and physician follow-up support.

 

Mechanical Thrombectomy Systems Hold the Strongest Commercial Position

Mechanical thrombectomy systems represent the broadest product opportunity because they participate in neurovascular, pulmonary, venous, peripheral arterial, dialysis-access, and selected cardiac procedures. The category includes aspiration systems, stent retrievers, rheolytic devices, mechanical coring systems, and products that combine aspiration with clot-disruption or capture components.

The commercial strength of this segment is reflected in Penumbra’s 2025 results. The company generated USD 947.9 million in global thrombectomy-product revenue, compared with USD 815.5 million in 2024. This represented year-over-year growth of 16.2%, adding USD 132.4 million in annual thrombectomy revenue. The growth rate exceeded the overall market’s forecast CAGR and was primarily associated with higher procedure and product volumes.

Aspiration platforms are receiving substantial development attention because a common pump or console can support multiple catheter sizes and indications. The commercial model combines reusable equipment with recurring disposable revenue, while software-assisted aspiration can create platform differentiation without requiring a completely new hospital workflow.

Stent retrievers remain important in neurovascular thrombectomy, particularly where physicians use combined aspiration-and-retrieval techniques. Medtronic’s Solitaire and Stryker’s Trevo portfolios compete with Penumbra’s aspiration-led systems and Johnson & Johnson MedTech’s EmboTrap range. Purchasing decisions increasingly consider first-pass clot removal, distal embolization, compatibility with access catheters, procedural consistency, and physician familiarity.

Catheter-directed thrombolysis retains a place in PE, DVT, and peripheral thrombosis, particularly where physicians want controlled local drug delivery. Its use can be limited by bleeding concerns, infusion duration, and intensive-care monitoring. Mechanical systems are positioned as drug-sparing alternatives, but wider routine use will depend on stronger comparative evidence.

 

Hospitals Buy Procedural Ecosystems Rather Than Individual Catheters

Hospitals and comprehensive stroke centers account for the central end-user segment because clot-removal procedures require emergency imaging, vascular access, specialist operators, anesthesia or sedation support, and management of bleeding or hemodynamic complications. Cath labs and interventional-radiology departments are particularly important for PE, DVT, peripheral arterial disease, and dialysis-access interventions.

Device companies are responding with complete procedural portfolios. Penumbra combines thrombectomy catheters with aspiration pumps, access sheaths, tubing, and clot-management software. Stryker now combines its neurovascular franchise with Inari’s FlowTriever, ClotTriever, Artix, and InThrill platforms. Boston Scientific participates through AngioJet and EKOS, while AngioDynamics is developing AlphaVac for pulmonary and large-vessel aspiration.

Penumbra’s direct-sales model generated approximately 90% of its 2025 revenue, showing how procedural support, physician education, and hospital account coverage affect commercial performance. Companies that cover access, clot removal, blood handling, and supporting equipment can increase revenue per procedure and reduce hospital dependence on multiple suppliers.

 

North America Leads Commercial Development

North America is the most commercially developed region because of its documented thrombectomy volumes, established stroke and PE programs, specialist adoption, and concentration of leading manufacturers. Penumbra generated 77.8% of its total 2025 revenue in the United States, making the country its dominant commercial market.

Penumbra’s global thrombectomy-product revenue increased 16.2% to USD 947.9 million in 2025, while U.S. thrombectomy sales rose 19.3%. The faster U.S. growth rate reflects procedure-volume expansion and continued adoption of aspiration and computer-assisted systems within established hospital accounts.

Europe has an established neurointerventional and peripheral vascular base, but access varies by country, region, and time of day. Recent CE marks for Penumbra’s THUNDERBOLT, ELEMENT, Lightning Bolt 12, and Lightning Bolt 6X portfolios broaden the products available in Europe, while procedure growth still depends on operator availability, treatment-center density, and reimbursement.

Asia-Pacific contains a substantial stroke and VTE burden but remains divided between high-access markets such as Japan, South Korea, Australia, and major Chinese cities and lower-access areas with limited interventional capacity. Expansion depends on stroke-network development, affordable device configurations, specialist training, and faster emergency transfer.

Latin America, the Middle East, and Africa offer longer-term potential but face similar infrastructure barriers. Partnerships with governments, teaching hospitals, professional societies, and regional distributors will be needed to convert disease burden into procedure volumes.

 

Consolidation Raises the Cost of Competing

Stryker’s acquisition of Inari Medical moved the company from a primarily neurovascular position into pulmonary embolism, DVT, peripheral arterial, and dialysis-access thrombectomy. Product launches following the transaction show that the acquisition was designed to create a wider vascular platform rather than preserve Inari as a single-indication franchise.

Boston Scientific announced an agreement in January 2026 to acquire Penumbra in a transaction valued at approximately USD 14.5 billion. The transaction value was more than 15 times Penumbra’s USD 947.9 million 2025 thrombectomy revenue, reflecting the strategic value placed on its installed hospital relationships, computer-assisted aspiration technology, and exposure to several vascular applications. Penumbra shareholders approved the merger proposal in May 2026.

The transaction would combine Boston Scientific’s cardiovascular distribution, AngioJet and EKOS presence with Penumbra’s neurovascular and computer-assisted aspiration portfolio. Medtronic, Johnson & Johnson MedTech, AngioDynamics, BD, Cook Medical, Imperative Care, Endovascular Engineering, and other specialized companies face competitors capable of offering products across several clot-management pathways.

Smaller companies can still compete through lower blood loss, easier navigation, narrower catheters, reduced capital requirements, or evidence in underserved indications, but hospital adoption requires clinical data, regulatory resources, training, inventory availability, and support for complex procedures.

 

Market Outlook

The strongest expansion is expected in mechanical thrombectomy for PE, DVT, peripheral arterial thrombosis, and broader neurovascular aspiration. New regulatory clearances, large acquisitions, Penumbra’s 16.2% thrombectomy revenue growth, and 19.3% U.S. thrombectomy sales growth indicate that device-based clot removal is capturing a larger role in selected vascular emergencies.

Growth will remain tied to patient selection, treatment-center capacity, and comparative evidence. IVC filters will stay selective following a 56.4% decline in Medicare insertions between 2013 and 2021, while catheter-directed thrombolysis will continue to compete with mechanical systems where drug exposure and hospital resource use are acceptable.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.24 Billion
Revenue Forecast in 2032	USD 3.58 Billion
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Mechanical Thrombectomy Systems, Aspiration Thrombectomy Systems, Stent Retrievers, Pharmacomechanical Thrombectomy Systems, Rheolytic Thrombectomy Systems, Catheter-Directed Thrombolysis Devices, Inferior Vena Cava Filters, Aspiration Pumps and Control Consoles, Thrombectomy Catheters and Access Components
By Application	Acute Ischemic Stroke, Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Peripheral Arterial Thrombosis, Thrombosed Dialysis Access, Intracardiac and Other Large-Vessel Thrombus
By End User	Hospitals, Comprehensive Stroke Centers, Cardiac Catheterization Laboratories, Interventional Radiology Centers, Vascular Surgery Centers, Ambulatory Surgical Centers, Office-Based Laboratories, Dialysis Access Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising clinical burden of stroke, pulmonary embolism, deep vein thrombosis, and peripheral vascular occlusion; growing preference for minimally invasive clot-removal procedures; expansion of thrombectomy-capable stroke and cardiovascular centers; continued advancement in aspiration, mechanical thrombectomy, and catheter-based technologies
Customization Option	Available upon request